Tirzepatide
Tirzepatide
Tirzepatide targets both the GIP and GLP-1 receptors simultaneously — a dual-hormone approach that human research has shown to produce superior outcomes for metabolic health compared to single receptor agents. In the SURMOUNT-1 trial, participants demonstrated weight reductions of up to 22.5% and significant improvements in blood glucose, cholesterol and blood pressure. Head-to-head data from SURPASS-2 confirmed tirzepatide outperforms semaglutide on both glycaemic control and weight reduction in human subjects.
Supplied as research-grade lyophilised peptide. Requires reconstitution with bacteriostatic water prior to use. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with Tirzepatide
Why researchers stack these
- 01GLP-1/GIP + GH axis — dual fat loss mechanisms
- 02Skin maintained through recomposition
- 03Mitochondrial metabolic amplification
Full research context
Tirzepatide handles systemic metabolic improvement through dual GLP-1/GIP agonism. Tesamorelin adds a direct pituitary GHRH mechanism for visceral adipose reduction that does not overlap with GLP-1 action — FDA-approved in this indication. GHK-Cu addresses the structural skin consideration that becomes apparent with significant body change. MOTS-c, the mitochondria-derived peptide, provides AMPK-mediated insulin sensitivity as the final layer of metabolic support.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting Tirzepatide
SURMOUNT-1: Tirzepatide Produces Up to 22.5% Body Weight Reduction in Human Trial
The SURMOUNT-1 trial enrolled 2,539 adults with obesity and demonstrated that once-weekly tirzepatide — a dual GIP and GLP-1 receptor agonist — produced weight reductions of up to 22.5% at 72 weeks in humans, with 96% of participants on the 15mg dose achieving at least 5% weight loss and 63% achieving 20% or more. These results in human subjects substantially exceeded the efficacy of prior licensed weight management medications and established tirzepatide as a landmark advancement in obesity pharmacology.
SURPASS-2: Tirzepatide Outperforms Semaglutide on HbA1c and Weight in Head-to-Head Human Trial
The SURPASS-2 trial directly compared tirzepatide against once-weekly semaglutide in 1,879 adults with type 2 diabetes. All three tirzepatide doses produced superior reductions in HbA1c (up to −2.07% vs −1.86%) and body weight (up to −11.2kg vs −5.7kg for semaglutide). At the 15mg dose, 27% of tirzepatide participants achieved HbA1c below 5.7% — the threshold for normal glycaemic status — establishing head-to-head superiority over the leading GLP-1 monotherapy in a human clinical trial.